Lucia Masarova, MD
Dr. Masarova is Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center in Houston.
Articles by Lucia Masarova, MD
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
Key takeaways from the top ASH abstracts in the myelofbrosis space.
A roundtable discussion starts with a conversation about the myelofibrosis treatment landscape.
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
The study is designed to evaluate the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in adults with ET.
Experts discuss emerging therapeutic targets, the impact of recently approved agents, and incorporating them into practice.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.